Paper Details

  1. Home
  2. Paper Details

Sunitinib side effects as surrogate biomarkers of efficacy.

Author: KollmannsbergerChristian

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Predictive markers of response to therapy are increasingly important with the expanding treatment options for metastatic renal cell carcinoma (mRCC). This review explores common mechanism-based adverse events associated with sunitinib, a first-line treatment for mRCC, and their potential use as biomarkers for treatment efficacy.
Paper Details　
Original Abstract of the Article :
With the proliferation of treatment options for the management of metastatic renal cell carcinoma (mRCC) over the past decade, predictive markers of response to therapy are becoming increasingly important. Sunitinib is commonly used in the first-line treatment of mRCC. Common mechanism-based adverse...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215302/

データ提供：米国国立医学図書館（NLM）

Sunitinib Side Effects: Clues to Treatment Efficacy?

Metastatic renal cell carcinoma (mRCC) is a challenging type of cancer that affects the kidneys. This research explores the potential of sunitinib side effects as biomarkers of treatment efficacy. Sunitinib is a drug commonly used to treat mRCC.

The researchers examined the relationship between sunitinib side effects and treatment response in mRCC patients. They found that common sunitinib side effects, such as hypertension, hypothyroidism, hand-foot syndrome, and neutropenia, could potentially serve as biomarkers of treatment efficacy. Imagine these side effects as subtle clues in the desert, hinting at the effectiveness of the treatment.

Unveiling the Desert's Secrets

This research highlights the potential of using side effects as biomarkers to personalize treatment for mRCC. It's like deciphering the secrets of a hidden oasis in the desert of cancer treatment.

Cancer Treatment: Finding the Right Path

This research emphasizes the importance of individualized cancer care and the need for personalized treatment approaches. Understanding the nuances of treatment response and potential biomarkers could lead to more effective and targeted cancer therapies.

Dr.Camel's Conclusion

This research presents a fascinating perspective on the role of side effects in cancer treatment. It explores the potential of using side effects as biomarkers to personalize treatment and improve outcomes for patients with mRCC. This research is like a new map in the desert of cancer research, guiding us toward more effective and individualized therapies.

Date :
  1. Date Completed n.d.
  2. Date Revised 2022-03-11
Further Info :

Pubmed ID

28096937

DOI: Digital Object Identifier

PMC5215302

Related Literature

Article Analysis
・Side Effects of sunitinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.